Seattle Genetics, Takeda Report Mixed Data on Cancer Drug

Although Seattle Genetics/Takeda lymphoma drug, Adcetris, met its main goal, investors weren't satisfied with the 5 percent improvement in survival rate.

June 27, 2017

Seattle Genetics Inc.'s lymphoma drug, co-developed with Takeda Pharmaceutical Co., met the main goal in a late stage study, but the data did not meet investor expectations on the advantages over standard of care, and company stocks took a hit.

According to a Reuters article, Adcetris did help blood cancer patients live longer without worsening their condition, but the difference in the patient survival rate was about 5 percent - 82.1 percent for the drug versus 77.2 percent in the control arm.

Read the full story